Kohei Shitara, Medical Oncologist at National Cancer Center Hospital East, Japan, shared a post on X:
“DESTINY-Gastric04 demonstrated significantly prolonged OS with T-DXd vs. PTX+RAM in HER2+ gastric cancer.
A major advancement for patients! Congratulations to all involved!”